Jian‐Qing Mi

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Ruijin Hospital, Gene Therapy Laboratory, Shanghai Institute of Hematology · ORCID：0000-0002-0769-5437

发表论文 210 篇 · 总被引 5041 次 · h-index 33

代表论文

• The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma (2025 · Blood · 被引 4)
• Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report (2025 · Blood · 被引 2)
• Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 1)
• Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia (2025 · Blood · 被引 1)
• Efficacy and safety of luspatercept in the treatment of anemia in allo-HSCT for patients with hematological diseases (2025 · Blood · 被引 1)
• A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager EMB ‐06 in Relapsed or Refractory Multiple Myeloma (2025 · American Journal of Hematology · 被引 1)